PitchBook-2025年一季度医疗技术公共报表和估值指南（英）-2025_6页_636kb

Medtech Public Sector Performance in Q1 2025

The medtech sector demonstrated resilience amid market turbulence during Q1 2025, outperforming broader indices like the S&P 500 (down 4.6%) and Nasdaq (down 10.4%). About half of large public companies saw share price increases, while median sector returns were positive despite mixed results. Key risks include unpriced-in tariff uncertainties, with analysts projecting double-digit revenue growth for diagnostics, consumer health, and medical devices, but more modest growth in life sciences (3%). Valuations have trended lower recently, with EV/EBITDA multiples around 20x and EV/revenue multiples in the 3-6x range, potentially offering upside but requiring caution due to earnings volatility and economic headwinds. Segments like diagnostics show strength, while consumer health is vulnerable to demand risks, and medical devices face input cost pressures. Earnings reports in the coming weeks may revise growth estimates, amplifying uncertainties.

For detailed company-specific data on stock returns, valuations, and financial metrics, refer to the full PitchBook report.